ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

アセトヒドロキサム酸

Acetohydroxamic Acid

HCID 1990
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
546-88-3
標準SMILES
CC(=O)NO
InChIKey
RRUDCFGSUDOHDG-UHFFFAOYSA-N
分子式
C2H5NO2
平均分子量
75.07 g/mol
単同位体質量
75.0320284

概要

Acetohydroxamic Acid can cause developmental toxicity according to state or federal government labeling requirements.

名称と識別子

優先名称
Acetohydroxamic Acid
IUPAC
N-hydroxyacetamide
現地名
アセトヒドロキサム酸
英語名
Acetohydroxamic acid
分子式
C2H5NO2
分子量
75.07

名称と別名

acetohydroxamic acidN-Hydroxyacetamide546-88-3Acetylhydroxamic acidLithostatAcetic acid, oximeMethylhydroxamic acidAcetohydroximic acidN-AcetylhydroxylamineAcethydroxamsaeurecetohyroxamic acidN-Acetyl hydroxyacetamide
名称をさらに表示
アセトヒドロキサム酸N-ヒドロキシアセトアミドアセトヒドロキシム酸アセチルヒドロキサム酸N-アセチルヒドロキシルアミンエタンヒドロキサム酸エタンヒドロキシム酸AHAAcetylhydroxylamineAcetomenadioneN-hydroxyacetimidic acidT-41BNSC 5073yangwosuan
Acido acetohidroxamicoAcide acetohydroxamiqueAcidum acetohydroxamicumn-hydroxy-acetamideDTXSID7022546NSC-1761364RZ82L2GY5DTXCID802546

データベース識別子

CAS
546-88-3
PubChem CID
1990
DTXSID
DTXSID7022546
ChEMBL
CHEMBL734
ChEBI
CHEBI:27777
UNII
4RZ82L2GY5
EC Number
208-913-8
Nikkaji
J23.285H

物性

構造計算による物性補完中

XLogP
-1.6
極性表面積
49.3 Ų
水素結合供与体数
2
水素結合受容体数
2
回転可能結合数
0
重原子数
5
形式電荷
0
複雑度
42.9

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
pH9.39 (aq soln)
SpringerMaterials PropertiesChemical shift
LogP · 3 件

log Kow= -1.59

-0.7

-1.59

Solubility · 2 件

5.09e+02 g/L

<0.2 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

DecompositionWhen heated to decomposition it emits toxic fumes of nitroxides.
Melting Point · 2 件

89-92 °C

90.5 °C

Physical DescriptionSolid
Dissociation Constants · 2 件

8.7 (at 25 °C)

pKa= 8.70

物理化学的性質

融点
88 · 88-90 °C (lit.)
沸点
133.7 °C · 133.7°C (rough estimate)
比重(密度)
1.2269 · 1.2269 (rough estimate)
屈折率
1.4264 · 1.4264 (estimate)
貯蔵温度
Keep in dark place,Inert atmosphere,Room temperature
溶解性
メタノール(適量)、水(適量)
外見
結晶性固体
酸解離定数(Pka)
8.7 · 8.70(at 25℃)
色
白色~淡黄色
水溶解度
水に溶ける。
Merck
14 · 14,63
BRN
1739019 · 1739019
安定性
湿気と温度に敏感
InChI
1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
InChIKey
RRUDCFGSUDOHDG-UHFFFAOYSA-N
SMILES
CC(NO)=O
CAS データベース
546 · 546-88-3(CAS DataBase Reference)
NISTの化学物質情報
Acetamide,N-hydroxy(546-88-3)
EPAの化学物質情報
Acetohydroxamic acid (546-88-3)

化学的性質

化学的特性White Crystalline Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H360 (96.1%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 51 reports by companies from 9 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationHazard Traits - Developmental Toxicity
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesRepr. 1B (96.1%)

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 3 件

Concurrent use of alcoholic beverages with acetohydroxamic acid has resulted in a nonpruritic, reddish, macular skin rash about 30 to 45 minutes after ingestion. The rash may be associated with a general feeling of warmth and tingling, and usually disappears spontaneously in 30 to 60 minutes.

Acetohydroxamic acid chelates iron and possibly other heavy metals with concurrent oral administration; this may result in reduced intestinal absorption of both; if iron therapy is indicated, parenteral administration of iron is recommended.

In vitro studies indicate that acetohydroxamic acid and methenamine have a synergistic effect in inhibiting increases in pH caused by urease-producing Proteus spp. and that acetohydroxamic acid potentiates the antibacterial effect of methenamine against these bacteria...

Human Toxicity Excerpts · 2 件

Acetohydroxamic acid was positive for mutagenicity in the Ames test.

Acetohydroxamic acid overdose has not been reported. However, if it should occur, concomitant reduction in platelets and/or white blood cells should be anticipated; reticulocyte count is likely to be elevated, and severe hemolysis may occur.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Acetohydroxamic acid

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 3 件

Acetamide, a metabolite or acetohydroxamic acid, has been shown to cause hepatocellular carcinoma in rats when used in very high doses.

...in long-term studies in rats, large oral dosages (e.g., 4 g/kg daily) of acetamide, a metabolite of acetohydroxamic acid, have been shown to cause hepatocellular carcinoma.

Evidence of toxicity did not occur when the drug was administered subcutaneously in mice at a dosage of 500 mg/kg daily for 60-100 days; however, evidence of cumulative toxicity, with death occurring at a mean of 21 days, occurred when the drug was administered subcutaneously at a dosage of 1 g/kg daily.

Antidote and Emergency Treatment · 1 件

Treatment of overdose: Administration should be stopped. There is no known specific antidote for acetohydroxamic acid overdose. Recommended treatment consists of the following: Monitoring - Close monitoring of hematologic status; Specific Treatment - Symptomatic treatment as necessary. Blood transfusions if required. Dialysis (considered possible but not yet proven).

Non-Human Toxicity Values · 3 件

LD50 Mouse ip 2.5 g/kg

LD50 Mouse oral 5 g/kg

LD50 Rat oral 4.8 g/kg

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
3
rtecs
AK8157000
ridadr
3263
毒性
mmo-sat 160 mmol/plate JOPHDQ 3,557,80
hs_code
29225090
risk_code
61-40
hazard_code
T
hazard_note
Toxic
safety_code
53-45-36/37/39-22
packing_group
II
Hazard Classifications
Repr. 1B
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
有毒物質データの
546-88-3(Hazardous Substances Data)

化学と産業

薬理情報

ATC Code · 2 件

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein BindingNo known binding
Pharmacodynamics · 1 件

Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.

Mechanism of Action · 2 件

Acetohydroxamic Acid reversibly inhibits the bacterial enzyme urease. This inhibits the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms, leading to a decrease in pH and ammonia levels. As antimicrobial agents are more effective in such conditions, the effectiveness of these agents is amplified, resulting in a higher cure rate.

Inhibits the hydrolysis of urea and production of ammonia in urine infected with urea-splitting bacteria, by reversible inhibition of the bacterial enzyme urease, and by the chelation of nickel, an essential component of urease enzymes. Such enzyme inhibition results in reduction of both urine alkalinity and ammonia concentration. The effectiveness of antibacterial medication is then enhanced and the formation of urinary calculi reduced.

Biological Half-Life · 2 件

5-10 hours in patients with normal renal function

...increases with increasing dose and reportedly ranges from about 3.5-10 hours in patients with normal renal function.

Metabolism/Metabolites · 2 件

35-65% of oral dose excreted unchanged in urine (which provides the drug's therapeutic effect).

...is metabolized to acetamide.

FDA Pharmacological Classification · 6 件

4RZ82L2GY5

ACETOHYDROXAMIC ACID

Established Pharmacologic Class [EPC] - Urease Inhibitor

Mechanisms of Action [MoA] - Urease Inhibitors

Acetohydroxamic acid is an Urease Inhibitor. The mechanism of action of acetohydroxamic acid is as an Urease Inhibitor.

ACETOHYDROXAMIC ACID

MeSH Pharmacological ClassificationCompounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Absorption, Distribution and Excretion · 6 件

Well absorbed from the GI tract following oral administration.

Well absorbed from gastrointestinal tract.

Well distributed throughout body fluids.

Elimination: Renal- Unchanged, 36 to 65%; as acetamide, 9 to 14%. Respiratory - As carbon dioxide, 20 to 40%.

In rodents, about 55% of an intraperitoneal dose is excreted in urine as unchanged drug, 15% as acetamide, and 10% as acetate within 24 hours; approximately 7% of the dose is excreted by the lungs as carbon dioxide and less than 1% is excreted in feces within 24 hours.

In mice, highest concentrations of the drug occur in the liver and kidney, while the lowest concentrations occur in the brain.

Cellular LocationsCytoplasm

用途と製造

UsesMEDICATION
応用分野 · 4 件

用途有機合成原料、ウレアーゼ阻害剤。

説明Acetohydroxamic acid is a potent, non-competitive and irreversible inhibitor of bacterial urease (Ki≈lO-7M). This enzyme, which is widely distributed in plants and bacteria, but not in mammalian cells, catalyzes the decomposition of urea to ammonia. Elevated urinary ammonia levels can reduce the antibacterial effectiveness of a number of agents. Thus, acetohydroxamic acid is useful as adjunctive therapy to decrease urinary ammonia and alkalinity in patients with chronic urea-splitting urinary infection. Such infections are a leading cause of recurring complications and death in paraplegics.

使用Acetohydroxamic acid is a potent inhibitor of bacterial urease activity and reduces urinary ammonia levels. 2-Acetohydroxamic acid loaded floating microspheres forms an efficient drug delivery system for the treatment of Helicobacter pylori.Acetohydroxamic acid was used:to study the mechanism of complexation of iron (III) with acetohydroxamic acid.to study the inhibitory mechanism of lansoprazole and omeprazole on Helicobacter pyloni.in urease inhibition studies.for in situ generation of nitrosocarbonylmethane as a Diels-Alder dienophile.Used in urease inhibition studies and for in situ generation of nitrosocarbonylmethane as a Diels-Alder dienophile.

一般的な説明Acetohydroxamic acid is a potent inhibitor of bacterial urease activity and reduces urinary ammonia levels. 2-Acetohydroxamic acid loaded floating microspheres forms an efficient drug delivery system for the treatment of Helicobacter pylori.

上流・下流製品情報

上流原料

ヒドロキシルアミン

下流製品

アセトアルドキシムカラセミド5-(トリフルオロメチル)ベンゾ[D]イソオキサゾール-3-アミン

関連反応

55 件
反応記録を作成
HRID 16396 の反応式
HRID 16396反応物として
HRID 82191 の反応式
HRID 82191反応物として
HRID 82777 の反応式
HRID 82777反応物として
HRID 241954 の反応式
HRID 241954反応物として
HRID 243823 の反応式
HRID 243823反応物として
HRID 245354 の反応式
HRID 245354反応物として
HRID 423274 の反応式
HRID 423274反応物として
HRID 475021 の反応式
HRID 475021反応物として
前へ1 / 7 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート